



3Q25

Results



Legal notice



This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our management and information to which the Company currently has access. Forward-looking statements include information about our current intentions, beliefs or expectations, as well as those of the members of the Company's Board of Directors and Officers.

Disclaimers regarding forward-looking statements and information also include information about potential or expected operating results, as well as statements that are preceded, followed or that include the words "believes", "may", "will", "continues", "expects", "predicts", "intends", "plans", "estimates" or similar expressions.

Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties and assumptions because they refer to future events, depending, therefore, on events that may or may not occur. Future results and value creation for shareholders may differ significantly from those expressed or suggested by forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.

3Q25 Highlights



Consolidated Net Revenue

Grew by 26.2%, reaching R\$356.5 million compared to 3Q24. For the accumulated period, this growth was 18.7%, totaling R\$805.3 million.

Adjusted EBITDA

Grew by 30.6%, reaching R\$97.6 million compared to 3Q24. For the accumulated period, this growth was 20.1%, totaling R\$166.0 million.



FINEP Award 2025

We were recognized with the FINEP Innovation Award 2025 – Southeast Region. This reinforces our commitment to solutions that promote food security and the sustainability of the Brazilian agribusiness sector.

Launch of 8 products in the last 12 months through internal development, partnerships, and new business initiatives.

3Q25 Highlights 2025 Launches



Production Animals

Companion Animals







NexLaner

USO VETERINÁRIO

ATENÇÃO: OBSERVAR AOS SEGUINTES PERÍODOS DE CAMBIO:
BOVINOS
ANTES O ABATE DOS ANIMAIS TRATADOS COM ESTE PRODUTO
DEVE-SE REALIZAR 30 DIAS APÓS A ÚLTIMA APLICAÇÃO
LÍQUIDO: ESTE PRODUTO NÃO DEVE SER APLICADO EM FÉRRAS
PRODUTIVAS DE LITE PARA O CONSUMO HUMANO

A UTILIZAÇÃO DO PRODUTO EM CONDIÇÕES DEPARTEIS DAS
INDICAÇÕES RECOMENDADAS PODE CAUSAR A PRESENCIA DE RESÍDUOS
ACIMA DOS LIMITES APROVADOS, TORNANDO O ALIMENTO DE
ORIGEM ANIMAL INAPROPRIO PARA O CONSUMO

Ectoparasitídeo
à base de Fluralaner
para bovinos

Contém
1 frasco com 1 L

 **ourofino**
saúde animal



NexLaner

USO VETERINÁRIO

Ectoparasitídeo à base
de Fluralaner para bovinos

INDICAÇÃO: Ectoparasitídeo para bovinos
Pré-abate - 30 dias após a aplicação do produto
para consumo humano

Não ingerir o produto nem o leite de animais tratados
com este produto durante o período de 30 dias

Conteúdo: 1 L

 **ourofino**
saúde animal

Financial Highlights



Growth in Production Animals, representing 29.1% compared to 3Q24.

Growth in Companion Animals, representing 9.8% compared to 3Q24.

Growth in International Operations, representing 28.1% compared to 3Q24.



Gross profit grew 22.1% compared to 3Q24, and 20.0% versus 9M24.

Adjusted Net Income grew 29.3% compared to 3Q24 and 14% versus 9M24.

Adjusted EBITDA reached R\$97.6 million, increasing 30.6% compared to 3Q24.



Leverage at 1.16x Net Debt/EBITDA, with 89.4% of debt in the long term and debt cost at the end of the period of 8.25% p.a.

Financial Highlights




In R\$ million	3Q24	3Q25	Chg %	9M24	9M25	Chg%
Total Net Revenue	282.6	356.5	26.2%	678.2	805.3	18.7%
Gross Profit	154.3	188.3	22.1%	344.5	413.5	20.0%
<i>Gross Margin</i>	54.6%	52.8%	-1.8 p.p.	50.8%	51.3%	0.5 p.p.
Adjusted EBITDA	74.7	97.6	30.6%	138.2	166.0	20.1 %
<i>Adjusted EBITDA Margin</i>	26.4%	27.4%	1.0 p.p.	20.4%	20.6%	0.2 p.p.
Adjusted Net Income	42.4	54.8	29.3%	70.8	80.7	14.0%
<i>Adjusted Net Margin</i>	15.0%	15.4%	0.4 p.p.	10.4%	10.0%	-0.4 p.p.


Consolidated Results

- Net revenue of R\$356.5 million, a growth of 26.2% in 3Q24.
- In 9M25, we reached net revenue of R\$805.3 million, an increase of 18.7% compared to 9M24.
- Slight decrease in gross margin, reaching 52.8%.


Net Revenue - R\$ million




Net Revenue - R\$ million



Gross profit - R\$million




Gross profit - R\$ million




Production animals Results

- Net revenue of R\$272.2 million, a growth of 29.1% in 3Q24.
- In 9M25, we reached net revenue of R\$594.5 million, representing a 21.2% increase compared to 9M24.
- Gross margin increased to 46.0% in 9M25.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million




Gross profit - R\$ million




Companion animals Result

- Net revenue of R\$45.2 million in 3Q25, an increase of 9.7% compared to 3Q24.
- In 9M25, net revenue reached R\$116.2 million, a growth of 4.8% versus 9M24.
- Gross margin reached 68.3% in 9M25.


Net revenue - R\$ million




Net Revenue - R\$ million



Gross profit - R\$ million




Gross profit - R\$ million




International operations Result

- Net revenue of R\$39.1 million, a growth of 28.1% compared to 3Q24.
- In 9M25, net revenue reached R\$94.6 million, an increase of 22.9% versus 9M24.
- Gross margin increased, reaching 63.3% in the quarter and 63.9% in 9M25.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million



Gross profit - R\$ million




Adjusted SG&A

- Adjusted SG&A totaled R\$77.3 million, representing 29.8% of net revenue, a dilution of 2.2%.
- Despite strategic investments in commercial and marketing structures, we are diluting expenses in relation to net revenue.


SG&A - R\$ million

— (%) Receita Líquida



SG&A - R\$ million


— (%) Receita Líquida



Research & development investments

- Investments in R&D reached 7.1% of net revenue in 9M25, totaling R\$56.8 million.
- The amount invested is aligned with the strategy of expanding the product portfolio with the goal of ensuring future revenues and creating value for the business.


R&D Investments- R\$ million



Adjusted EBITDA


- Adjusted EBITDA growth outpacing revenue – up 30.6% compared to 3Q24 and 20.1% in 9M25

Adjusted EBITDA- R\$ million



Adjusted EBITDA Margin

Adjusted EBITDA - R\$ million




Adjusted EBITDA Margin

Cash position

- Operating cash generation reached R\$32.5 million in 9M25, bringing total cash availability to R\$206.6 million.
- Capital reduction carried out in January 2025.

Cash Position - R\$ Million





We remind you that on January 31, 2025, as previously communicated and approved at the Extraordinary General Meeting held in October 2024, we completed the payment of the capital reduction in the amount of R\$120 million to shareholders. This move is aligned with our strategy of creating value for all shareholders without compromising the company's growth or investment capacity, in line with the leverage achieved over the past four years.

Thanks to our strong cash generation, within the first few months of the year we were able to reintegrate nearly 50% of the amount distributed to shareholders. This reaffirms our strong ability to generate and convert cash from operations, as well as the efficiency of our financial management, which ensures a solid structure aligned with Ourofino's strategic needs.

Capital Structure

- Leverage at 1.16x EBITDA and average debt cost at the end of 9M25 of 8.25%


Composition




Capital Structure

- 41.5% of gross debt matures in more than 5 years.

Aging - R\$ million



Banking Debt Aging - R\$ million



Q&A

Reimagining Animal Health

We produce solutions and services to feed the world and increase the longevity of companion animals.





Ourofino S.A.
(B3:OFSA3)

Investor Relations Department

ri@ourofino.com



(16) 3518-4098



ri.ourofino.com



Marcelo Silva

IR Team